Antibiotic Resistance Market By Disease Type (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Pathogen Type (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others) Drugs Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026
antibiotic resistance market is growing at a substantial CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth. Few of the major competitors currently working in the global antibiotic resistance market are Achaogen, Inc, Nabriva Therapeutics plc, BioVersys AG, Johnson & Johnson Services, Inc, Destiny Pharma plc, Armata Pharmaceuticals, Inc, Westway Health, NEMESIS BIOSCIENCE LTD, Tetraphase Pharmaceuticals, The Medicines Company, ALLERGAN, Merck & Co., Inc., Pfizer Inc, CARB-X, MELINTA THERAPEUTICS, INC, , Novartis AG, Vertex Pharmaceuticals Incorporated, GlaxoSmithKline Plc, AbbVie Inc, F. Hoffmann-La Roche Ltd and others.
Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-antibiotic-resistance-market
Global antibiotic resistance market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global antibiotic resistance market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Market Definition: Global Antibiotic Resistance Market
Antibiotics are the medications that are widely used for the treatment of various types of infections. Antibiotics resistance develops when infections stop responding to the existing antibiotics. It becomes major health and economic challenges of global public health concern. It is potentially threaten to the effective treatment of the infectious infections.
According to the statistics published by Johnson & Johnson Services, Inc, antibiotics resistance was responsible for over 700,000 deaths every year worldwide including more than 50,000 in the U.S and the Europe. Increases of cases of prevalence rate, Advances in antibiotics and immunization and accelerate demanding of novel therapies are the drivers for market growth.
- Increases of cases of prevalence rate of infectious diseases worldwide is act as drivers for market growth
- Advances in nutrition, antibiotics and immunization is accelerating the market growth
- Accelerate demanding of novel therapies is enhancing the market growth
- Prevalence of indoor as well as outdoor infections is propelling the market growth
- Effective treatment is either unavailable or unaffordable is restraining the market growth
- Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth of the market.
- Lack of trained personnel and stringent safety regulations is hampering the market growth
Grab Your Report at an Impressive 30% Discount! Please click [email protected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-antibiotic-resistance-market
Segmentation: Global Antibiotic Resistance Market
By Disease Type
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
By Pathogen Type
- Acinetobacter Baumannii
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Streptococcus Pneumoniae
By Drugs Class
By End Users
- Specialty Clinics
- North America
- South America
- Middle East & Africa
Key Developments in the Market:
In August 2019, Nabriva Therapeutics plc received approval from the FDA for Xenleta (lefamulin) a first-in-class semi-synthetic pleuromutilin antibiotic indicated as a first-line monotherapy for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The FDA approval of Xenleta is significant milestones for the company to address the growing threat of antimicrobial resistance and provide efficient treatment options for patients with community-acquired bacterial pneumonia (CABP).
In May 2018, CARB-X entered into research collaboration with MELINTA THERAPEUTICS, INC to develop pyrrolocytosine, a new class of antibiotics for the treatment of drug-resistant bacterial infections. Under the terms of the deal, MELINTA THERAPEUTICS, INC received USD 2.3mm and is eligible to receive up to USD 3.9mm upon achievement of certain future milestones. The collaboration will immensely enhance development and innovative approaches to address the rising threat of drug resistance worldwide.
Reasons to Purchase this Report
- Current and future of global antibiotic resistance market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: [email protected]